Abstract: The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.
Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
Type:
Grant
Filed:
November 3, 2003
Date of Patent:
October 31, 2006
Assignees:
Diagnostic Hybrids, Inc., Health Research Incorporated
Inventors:
Laura Gillim-Ross, Jill Taylor, David R. Scholl, David E. Wentworth, Joseph D. Jollick
Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.
Abstract: The present invention provides a recombinant virus which is efficacious and highly safe in preventing the onset of SARS infection and a vaccine for SARS coronavirus containing the same. The recombinant virus of the invention can express a SARS coronavirus gene.
Type:
Application
Filed:
October 11, 2005
Publication date:
August 27, 2009
Applicants:
Post Genome Institute Co., Ltd., The Chemo-Sero-Therapeutic Research Institute
Abstract: The present invention provides nucleotide sequences from SARS (Serve Acute Respiratory Syndrome) coronavirus genomes, as well as the applications of the partial fragments thereof in preparing DNA vaccine or expressing corresponding proteins. Furthermore, the present invention also provides the uses of said proteins in preventing and treating diseases, and preparing antibodies.
Abstract: The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents and as a vaccine.
Type:
Application
Filed:
July 20, 2011
Publication date:
April 5, 2012
Inventors:
Sylvie VAN DER WERF, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.
Type:
Grant
Filed:
January 19, 2006
Date of Patent:
November 17, 2009
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Ralph S. Baric, Rhonda Roberts, Boyd Yount, Kristopher M. Curtis
Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.
Type:
Application
Filed:
April 6, 2010
Publication date:
March 17, 2011
Inventors:
Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
Abstract: Provided are a bovine rotavirus fusion protein and calf diarrhea multivalent vaccine. The bovine rotavirus fusion protein contains a VP6 fragment, wherein the VP6 fragment contains an amino acid sequence as represented by SEQ ID NO. 4, and at least one loop region of the following (a)˜(c) is substituted with an antigenic epitope derived from bovine coronavirus and/or an antigenic epitope derived from E. coli: (a) amino acid residues of sites 168-177; with an amino acid sequence as represented by SEQ ID NO. 1; (b) amino acid residues of sites 194-205; with an amino acid sequence as represented by SEQ ID NO. 2; and (a) amino acid residues of sites 296-316, with an amino acid sequence as represented by SEQ ID NO. 3, The bovine rotavirus fusion protein contains a plurality of antigenic epitopes, and can enable a host to generate a plurality of antibodies after immunizing the host.
Type:
Grant
Filed:
April 16, 2021
Date of Patent:
April 9, 2024
Assignee:
TECON BIOPHARMACEUTICAL CO., LTD.
Inventors:
Sun He, Yiping Pan, Guoqing Zhang, Pengxian Yan, Na Xi, Miaomiao Guo, Shengdong Xiao, Tianzeng Li, Rui Han, Yumeng Wang, Jiubin Du, Pei Zheng, Jian Cao
Abstract: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods.